Rosemont Pharmaceuticals has entered a definitive merger agreement to acquire Aytu BioPharma, with a wholly owned Rosemont subsidiary set to commence a tender offer for all outstanding Aytu common stock at a 41.1% premium to Aytu's 30-day volume-weighted average share price.
Aytu is a U.S. specialty pharmaceutical company focused on innovative medicines for complex central nervous system diseases, with an established adult and pediatric CNS specialty business. Rosemont said combining the portfolios, expertise and commercial capabilities, including omnichannel and digital marketing, will accelerate its U.S. growth strategy and specialty pharmaceutical market position.
Rosemont CEO Alok Sonig said Aytu brings talented people, a differentiated portfolio and proven commercial capabilities, which combined with Rosemont's product development, regulatory, manufacturing and commercial expertise can build a platform for future growth. Aytu CEO Josh Disbrow said the transaction delivers compelling value to shareholders and reflects the trust the company has earned from patients and healthcare providers.
The tender offer requires shares representing at least a majority of outstanding Aytu common stock, and exercise or termination of certain outstanding warrants. Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, with Aytu filing a Schedule 14D-9 concurrently, and the transaction, unanimously approved by Aytu's board, is anticipated to close in late December 2026.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!